Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoinflammatory and Chronic Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NLRC4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NLRC4 Recombinant Protein (CARD Domain / Functional Fragments) High purity (>90%), Endotoxin controlled. Sequence Verified. Sf9 or E. coli expressed. |
View NLRC4 Products |
| Gene Delivery | NLRC4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based ASC-speck formation assays. |
View NLRC4 Products |
| Benchmark Ab | Anti-NLRC4 Recombinant Antibody Recombinant positive control for western blot, immunoprecipitation, and flow cytometry. |
View NLRC4 Products |
| Validator | NLRC4 siRNA Set For knockdown verification in macrophage and epithelial cell models. |
View NLRC4 Products |
| Related Target A | NLRP3 Co-inflammasome target. Vital for counter-screening to ensure NLRC4 pathway selectivity. |
View NLRP3 Products |
| Related Target B | CASP1 (Caspase-1) Immediate downstream protease activated by the NLRC4 inflammasome complex. |
View CASP1 Products |
| Related Target C | GSDMD (Gasdermin D) Downstream pore-forming effector of pyroptosis mediated by NLRC4/Caspase-1 activation. |
View GSDMD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational stability of multi-domain intracellular proteins | Domain-specific truncated proteins (e.g., CARD domain) with >90% purity, minimizing aggregation in biochemical screening. |
| Selectivity profiling within the NLR family | NLR family homolog panel proteins (NLRP3, NOD1, NOD2) strictly verified by sequence and mass spectrometry. |
| Lack of reliable positive controls for cellular activation | Sequence-verified clinical benchmark antibodies and high-titer lentivirus for stable cell line construction. |
| High rate of false positives in phenotypic screening | Validated siRNA sets included to confirm target specificity in primary human cells. |
Live NLRC4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NLRC4 therapeutics is intensifying, with major players shifting focus from traditional downstream cytokine blockade to direct intracellular inflammasome modulation. As first-generation NLRP3 inhibitors pave the clinical path, the next wave of R&D is targeting NLRC4 for its highly specific role in intestinal epithelial barrier protection, macrophage activation syndrome (MAS), and severe autoinflammatory syndromes. Developing selective small molecules that disrupt NAIP-NLRC4 oligomerization or NLRC4-CARD domain interactions represents the frontier of precision immunology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Roche (Inflazome), Preclinical Biotechs | NLRC4-MAS, Autoinflammatory Enterocolitis, COPD | Selectivity Assay (Need Mutant vs WT Proteins and NLR family homolog panels) |
| Downstream Biologics | AB2 Bio, Sobi | Macrophage Activation Syndrome, Still's Disease | Functional Neutralization Verification (Need high-purity GSDMD and CASP1 proteins) |
| Gene Therapy / RNAi | Academic Spin-offs, Preclinical Startups | Severe Hereditary Inflammasomopathies | In vitro knockdown validation (Need verified siRNA sets and Lentivirus-driven over-expression) |